299 related articles for article (PubMed ID: 1726842)
1. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evaluation of tumor markers in patients with colorectal cancer].
Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N
Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer.
Ucar E; Semerci E; Ustun H; Yetim T; Huzmeli C; Gullu M
Adv Ther; 2008 Oct; 25(10):1075-84. PubMed ID: 18821070
[TBL] [Abstract][Full Text] [Related]
4. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
5. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer.
Carpelan-Holmström MA; Haglund CH; Järvinen HJ; Roberts PJ
Anticancer Res; 1996; 16(2):981-6. PubMed ID: 8687164
[TBL] [Abstract][Full Text] [Related]
6. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in the upper intestinal tract--stomach and pancreas].
Pointner R; Conrad F; Schwab G
Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
[TBL] [Abstract][Full Text] [Related]
8. [The role of tumor markers in diagnosing metastases of gastric cancer: preoperative diagnostics (part I)].
Kurygin AA; Maĭstrenko NA; Khrykov GN; Beliak NP
Vestn Khir Im I I Grek; 2009; 168(4):16-9. PubMed ID: 19947409
[TBL] [Abstract][Full Text] [Related]
9. A new radioimmunoassay detecting early stages of colon cancer: a comparison with CEA, AFP, and Ca 19-9.
Chester SJ; Maimonis P; Vanzuiden P; Finklestein M; Bookout J; Vezeridis MP
Dis Markers; 1991; 9(5):265-71. PubMed ID: 1724634
[TBL] [Abstract][Full Text] [Related]
10. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
11. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
[TBL] [Abstract][Full Text] [Related]
12. Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
Lindmark G; Kressner U; Bergström R; Glimelius B
Anticancer Res; 1996; 16(2):895-8. PubMed ID: 8687147
[TBL] [Abstract][Full Text] [Related]
13. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
15. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
16. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
17. [An autopsy case of a gastric cancer associated with elevated AFP, CEA and CA19-9].
Nakamura Y; Hozumi T; Ohkita M; Masuda S; Maeda M; Okada K; Chinzei T; Yamashiro K; Harui M; Hosokawa I
Gan No Rinsho; 1988 Feb; 34(2):213-8. PubMed ID: 2450214
[TBL] [Abstract][Full Text] [Related]
18. [Standards, options and recommendations for tumor markers in colorectal cancer].
Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
[TBL] [Abstract][Full Text] [Related]
19. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer.
Sato T; Nishimura G; Nonomura A; Miwa K; Miyazaki I
Hepatogastroenterology; 1999; 46(26):914-9. PubMed ID: 10370638
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
